KOKohei Ogawa

Kohei Ogawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kohei Ogawa has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503

    by Masayoshi Dazai, Satoshi Yuki, Hiroshi Nakatsumi, Yasushi Tsuji, Yoshimitsu Kobayashi, Kazuteru Hatanaka, Hiroyuki Okuda, Ayumu Hosokawa, Koichi Furukawa, Kohei Ogawa, et al.

    Introduction: The J003 trial and RECOURSE trial revealed the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer (mCRC). In March 2014, TAS-102 was approved in Japan, however, there are few studies exploring the efficacy and safety of TAS-102, particularly in the daily practice use. Therefore, we performed this retrospective analysis in order to investigate the real-world clinical practice of TAS-102 for patients with mCRC.

  • Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment

    by Shinya Kajiura, Ayumu Hosokawa, Hiroki Yoshita, Yuko Ueda, Akira Ueda, Hiroshi Mihara, Takayuki Ando, Haruka Fujinami, Jun Nishikawa, Kohei Ogawa, et al.

    Objectives: To date, no second-line chemotherapy regimen for esophageal squamous cell carcinoma (SCC) has been established. This clinical trial aimed to assess the optimum dose of docetaxel plus nedaplatin (cis-diammine-glycolate platinum) as second-line chemotherapy. Methods: Patients with metastatic or recurrent esophageal SCC after treatment with cisplatin plus 5-fluorouracil received docetaxel (50 or 60 mg/m2) plus nedaplatin (70 mg/m2) on day 1 every 4 weeks. The recommended dose was based on dose-limiting toxicities defined during the first cycle. Results: From February 2009 to November 2011, 9 patients were enrolled in the study. Their median age was 62 years (range, 58 to 72 y). Six patients had undergone radiotherapy and 4 had undergone surgical resection of primary lesions. Dose-limiting toxicities were observed in 2 patients at dose level 1 (60 mg/m2 docetaxel, 70 mg/m2 nedaplatin) but not at dose level 0 (50 mg/m2 docetaxel, 70 mg/m2 nedaplatin). Thus, the maximum tolerated dose was established at dose level 1. No severe nonhematological toxicity was observed. No patient achieved complete response, but 2 (22%; 95% confidence interval, 0%-49%) achieved partial response and 3 had stable disease. Median progression-free and overall survival times were 2.1 and 9.5 months, respectively. Conclusions: Docetaxel plus nedaplatin chemotherapy seems to be a safe and feasible second-line regimen for the treatment of esophageal SCC. We recommend the administration of 50 mg/m2 docetaxel (day 1) plus 70 mg/m2 nedaplatin (day 1) every 4 weeks in a phase II study.


    • 1 November 2013
      • Vol. 33  (11) , 5107-11

    Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.

    by Akira Ueda, Ayumu Hosokawa, Kohei Ogawa, Hiroki Yoshita, Hiroshi Mihara, Takayuki Ando, Shinya Kajiura, Haruka Fujinami, Jun Nishikawa, Masami Minemura, et al.

    Irinotecan alone and plus mitomycin C have been proven to be effective as second-line chemotherapy for advanced gastric cancer. The objective of the present study was to compare the efficacy and safety of irinotecan alone (CA) and with mitomycin C (CM) in clinical practice. Between November 2006 and December 2011, 46 patients with advanced gastric cancer refractory to fluoropyrimidine and platinum were treated with CM (n=22) or CA (n=24). Baseline characteristics of the patients were similar in the two treatment groups, with the exception of the sex ratio. The median progression-free survival was 3.9 months in the CM arm and 3.7 months in the CA arm (p=0.25), and the median overall survival was 9.6 and 8.7 months (p=0.36), respectively. The overall response rate was 18% in the CA arm and 9% in the CM arm (p=0.38). Grade 3/4 neutropenia (45% vs. 25%), anemia (36% vs. 4%), febrile neutropenia (14% vs. 8%), anorexia (14% vs. 8%) tended to be higher in the CM arm than in the CA arm. Although the efficacy of CM and CA for advanced gastric cancer refractory to fluoropyrimidine and platinum was not significantly different, CM tended to lead to greater incidence of adverse events in clinical practice.


  • Su1982 Favorable Prognostic Factors in Advanced Gastric Cancer Patients Ineligible for Criteria of the Clinical Trial

    by Hiroki Yoshita, Takayuki Ando, Ayumu Hosokawa, Yuko Ueda, Shinya Kajiura, Akira Ueda, Sohachi Nanjo, Yushi Hasumoto, Haruka Eujinami, Jun Nishikawa, et al.

  • Early decline of CA125 to chemotherapy in advanced gastric cancer with peritoneal effusion.

    by Takayuki Ando, Ayumu Hosokawa, Yuko Ueda, Hiroki Yoshita, Akira Ueda, Hiroshi Mihara, Yuushi Hasumoto, Haruka Fujinami, Shinya Kajiura, Jun Nishikawa, et al.

    97 Background: Serum cancer antigen 125 (CA125) has been shown to be elevated in gastric cancer with peritoneal effusion, and to be a biomarker for monitoring the efficacy of chemotherapy in ovarian cancer. Therefore, we retrospectively evaluated the hypotheses that an early decline of CA125 to chemotherapy predicted the response of peritoneal effusion and survival in advanced gastric cancer with peritoneal effusion. Methods: CA125 concentration was measured at baseline and 4 to 7 weeks after induction of chemotherapy. The patients whose CA125 decreased at least 25% after chemotherapy were categorized as a decline group, and the other patients were defined as non-decline group. Baseline peritoneal effusion was classified in three levels with CT scan: none; mild; severe. Mild effusion was localized in the pelvic cavity or surface of the liver, and severe effusion was extended throughout the abdominal cavity. CT scan was followed every 2 months after chemotherapy, and the response in peritoneal effusion was defined to decrease at least one level. The median PFS and OS were also evaluated in two groups. Results: 121 advanced gastric cancer patients were assessable for analysis of CA125 concentration between April 2006 and April 2012. In 59 patients with a baseline CA125 below the upper limit of normal (ULN), 16 patients (27%) had peritoneal effusion, and in 75 patients with a baseline CA125 equal to above ULN, 54 patients (73%) had peritoneal effusion (P < 0.0001). Baseline characteristics of 54 patients with effusion and elevated CA125 were as follows: median age = 63 years (range 38-81), male : female = 38 : 16, PS 0-1 : 2-3 = 35 : 19, diffuse: intestinal = 40 : 14, mild effusion : severe effusion = 41 : 13. In 26 patients of the decline group, the response of effusion was 45%, the median PFS was 146 days, and the OS was 308 days. In 28 patients of the non-decline group, the response of effusion was 4%, the median PFS was 67 days, and the OS was 192 days. There were significant differences in response of peritoneal effusion (P = 0.001), PFS (P = 0.0002), and OS (P = 0.005). Conclusions: Early decline of CA125 has potential clinical utility in predicting favorable response and survival to chemotherapy in advanced gastric cancer patients with peritoneal effusion.

  • Preventive effect of rikkunshito, traditional Japanese medicine, for chemotherapy-induced nausea and vomiting.

    by Shinya Kajiura, Ayumu Hosokawa, Sohachi Nanjyo, Hiroki Yoshita, Nobuhiro Suzuki, Hidemoto Yamawaki, Yuko Ueda, Akira Ueda, Hiroshi Mihara, Yuushi Hasumoto, et al.

    131 Background: Supportive therapies are being developed for chemotherapy-induced nausea and vomiting (CINV). Rikkunshito is a Kanpo medicine, which is a part of traditionally practiced Japanese-based ancient Chinese medicine. It has been reported to be effective against cisplatin-induced anorexia in rats. In the present study, we evaluated the preventive effect of Rikkunshito for CINV in patients receiving high-dose cisplatin. Methods: We selected subjects who received chemotherapy including cisplatin (≥60mg/m2) for gastric or esophageal cancer between April 2010 and August 2012 at our institution. We targeted 20 cases treated without a reduction in the anti-cancer medication in the second course and added 7.5g/day of Rikkunshito, orally administered for seven days, to their second course treatment regimen. All cases were treated with 5-HT3 receptor antagonist and steroid, and palonosetron for the prevention of CINV in their first and second courses. We evaluated the complete response (CR, defined as no emesis and no rescue medication) rate and other toxicity, according to CTCAE v4.0, of the first and second courses. Results: The median age of the patients was 63 years (range, 49–77 years). The chemotherapy regimens were cisplatin + 5-FU in 15 cases with esophageal cancer, cisplatin + S-1 in five cases with gastric cancer. Anorexia in the first course was grade 0/1/2 = 5/11/4, but had been mitigated in the second course to grade 0/1/2 = 12/6/2 (P = 0.042). CR rate was 75.0% in the first course (95% CI, 56.0%–94.0%) and by the second course had improved to 95.0% (95% CI, 85.4%–100%). And about the other major toxicity, there was no significant difference between first and second courses. Conclusions: These results suggest that Rikkunshito has the potential to improve CINV in patients receiving high-dose cisplatin.

  • A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients

    by Kohei Ogawa, Takao Ueno, Ken Kato, Hitoshi Nishitani, Kohei Akiyoshi, Satoru Iwasa, Takako Eguchi Nakajima, Tetsuya Hamaguchi, Yasuhide Yamada, Ayumu Hosokawa, et al.

    Background Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has showed clinical benefits in patients with metastatic colorectal cancer. Periodontitis has been observed infrequently in bevacizumab-containing chemotherapy in clinical practice. The purpose of this study was to retrospectively investigate bevacizumab-related periodontitis in metastatic colorectal cancer patients. Methods From January 2008 to March 2010, 274 patients received bevacizumab-containing chemotherapy at the National Cancer Center Hospital in Tokyo. Patients who had consulted the dentist for periodontitis were included in the study. We examined the interval between the initiation of the first bevacizumab administration and the day of the consultation with the dentist. Periodontitis was evaluated before and after conservative therapy. Results Twenty-six patients (9.5 % of the 274 metastatic colorectal cancer patients) were included in this study. The median age was 60 years (range 30–79 years). Nineteen (73 %) patients had a good performance status of 0. The combination regimens used with bevacizumab were infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX, 53 %); infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI, 27 %); capecitabine + oxaliplatin (CapeOX, 8 %); S-1 + oxaliplatin (8 %); and S-1 + irinotecan (4 %). The median time from bevacizumab administration to the consultation with a dentist for periodontitis was 69 days (range 12–390 days), and the median number of bevacizumab administrations was 3.5 (range 1–25). After conservative therapy, 22 (85 %) patients with periodontitis showed an improvement. Conclusions Periodontitis occurred frequently in patients receiving bevacizumab. The conservative therapy for periodontitis was very effective, and the prophylaxitic treatment was important.


    • 1 July 2012
      • Vol. 32  (7) , 2545-50

    Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.

    by Ayumu Hosokawa, Kohei Ogawa, Takayuki Ando, Nobuhiro Suzuki, Akira Ueda, Shinya Kajiura, Yuka Kobayashi, Yuji Tsukioka, Naoki Horikawa, Kazuhisa Yabushita, et al.

    A combination of 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX) is a standard regimen for the chemotherapy of metastatic colorectal cancer. The major dose-limiting toxic effect of oxaliplatin is neurotoxicity. The aim of this study was to evaluate the preventive effects of traditional Japanese medicines, goshajinkigan and shakuyakukanzoto on oxaliplatin-induced neurotoxicity with FOLFOX. Between July 2006 and November 2008, a total of 44 patients with metastatic colorectal cancer received modified FOLFOX6 or FOLFOX4, as first-line chemotherapy at three institutions. They concurrently received either goshajinkigan (group A, n=20) or shakuyakukanzoto (group B, n=24) for neurotoxicity reduction. The median number of treatment cycles and the median cumulative dose of oxaliplatin were 12 cycles (range, 4-19) and 898 mg/m(2) (range, 340-1255) in group A and 10.5 cycles (range, 6-20) and 845 mg/m(2) (range, 510-1480) in group B. Eighteen patients in group A and 24 in group B received oxaliplatin in a cumulative dose exceeding 500 mg/m(2). At a dose of 500 mg/m(2) oxaliplatin, grade 1-2 toxicity occurred in 10 patients of group A and in 7 of group B, but there was no grade 3 or higher toxicity in either group. The response rate of the 38 patients with measurable lesions was 50.0% (9/18) in group A and 65% (13/20) in group B. The administration of traditional Japanese medicine may reduce oxalipatin-induced neurotoxicity without negatively affecting tumor response in patients with colorectal cancer who undergo FOLFOX therapy.


  • Sa1663 Evaluation of the Efficacy of Hemostatic Methods for Peptic Ulcer Patients Receiving Anticoagulants: Endoscopic Clipping, Hypertonic Saline-Epinephrine Injection, and Combination of the Two

    by Haruka Fujinami, Ayumu Hosokawa, Kohei Ogawa, Jun Nshikawa, Shinya Kajiura, Hiroshi Mihara, Takayuki Ando, Toshiro Sugiyama

  • Open Access

    Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study

    by Kohei Ogawa, Ayumu Hosokawa, Akira Ueda, Seiko Saito, Hiroshi Mihara, Takayuki Ando, Shinya Kajiura, Mitsuhiro Terada, Yuji Tsukioka, Naoki Horikawa, et al.

    Background. S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear.Methods. We retrospectively studied the efficacy, toxicity, and survival of irinotecan plus mitomycin C in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin.Results. Twenty-four patients were studied. Prior chemotherapy was S-1 plus cisplatin in 15 patients, S-1 plus cisplatin and docetaxel in 8, and 5-fluorouracil plus cisplatin with radiotherapy in 1. The overall response rate was 17.4%. The median overall survival was 8.6 months, and the median progression-free survival was 3.6 months. Grade 3 or 4 toxicities included leukopenia (33%), neutropenia (50%), anemia (33%), thrombocytopenia (4%), anorexia (13%), diarrhea (4%), and febrile neutropenia (13%).Conclusion. A combination of irinotecan and mitomycin C is potentially effective in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin.